Last updated: April 24, 2026
CN112654356: Scope, Claims, and China Patent Landscape Analysis
Scope summary (what CN112654356 covers): CN112654356 is a Chinese patent application/publication that claims a drug product and/or drug formulation and its preparation for a specific therapeutic agent (the active ingredient and exact formulation parameters must match the claims as filed). The scope in China practice typically concentrates on composition-by-structure and composition-by-procedure, plus any pharmaceutical dosage forms and stability/performance parameters explicitly recited in the independent claims.
Claims summary (what the patent legally protects): The protectable subject matter is driven by (1) an independent claim that defines the composition/formulation (active ingredient identity and quantitative ranges), and (2) dependent claims that narrow to dosage forms, manufacturing steps, excipients, and physicochemical or performance metrics (solubility, dissolution, stability, particle size, encapsulation, etc.) when those metrics appear in the claim language. The enforcement boundary in China is determined by claim construction using the Chinese specification and prosecution history context, and by whether an accused product falls within the claimed ranges and defined composition elements.
Patent landscape impact: For business and R&D decisions, CN112654356 should be evaluated as a blocker or license candidate against generic/formulation challengers in China, because CN112654356’s claims (once granted) can restrict:
- Same active ingredient + same formulation composition within the claimed ranges
- Same dosage form and/or manufacturing route as claimed
- Same performance-defined formulation if the metrics are part of the claim
Key diligence point: In China, competitors often avoid literal infringement by changing quantitative ranges, switching excipient systems, changing process parameters, or using different polymorph/particle size forms if the claims include those details. The practical risk level depends on how tightly the claims define the formulation and process and whether they are “result” claims tied to measurable performance.
What does CN112654356 claim in legal scope terms?
Independent claim structure typical for CN112654356-type Chinese drug filings
- Composition claim: active drug identity plus formulation components and numeric ranges.
- Dosage form claim: tablets/capsules/granules/injection/lyophilizate/etc. with defined composition.
- Process claim: preparation method steps (mixing, granulation, coating, sterilization, freeze-drying, milling, encapsulation, etc.) with ordered steps and/or parameter ranges.
Scope boundary drivers
-
Active ingredient definition
- Whether the claim is limited to a specific chemical entity (name/structure/chemical formula).
- Whether it is broad (generic “compound of formula (I)”) or narrow (single compound).
-
Quantitative boundaries
- Weight percent (wt%) or mg per unit dosage.
- Ratios among key excipients.
- Concentration ranges for drug solutions/suspensions.
-
Formulation architecture
- Solid dispersion vs. nanosuspension vs. matrix tablet vs. capsule shell vs. liposome/solid lipid nanoparticles, where claimed.
- Whether excipients are recited mandatorily or as “selected from” alternatives.
-
Process and method limitations
- Step order.
- Critical parameters (temperature, time, pH, mixing speed, particle size target).
- Conditions tied to achieving a particular property (dissolution profile, stability).
-
Performance metrics
- If included in claims, they create both an infringement hook (product must meet metric) and an evidentiary burden (how metrics are measured and compared).
What is the claim set and how is it layered (independent vs dependent)?
A CN drug publication generally follows a claim dependency ladder where:
- Claim 1 is the broadest independent claim.
- Claims 2-n depend from Claim 1, adding constraints (e.g., specific excipients, particle size, dissolution acceptance criteria, manufacturing step parameters).
- Method vs composition are either both present or the patent focuses on one category.
Practical implications for scope
- If the independent claim is composition-focused, infringement turns on whether the accused formulation matches the claimed component and ratio ranges.
- If dependent claims add process parameters, infringement analysis expands to whether the accused manufacturing method is used.
- If dependent claims are performance-defined, technical testing and expert testimony become central for infringement/validity disputes.
Where does CN112654356 sit in the China filing-to-grant timeline?
How CN112654356 typically maps onto CNIPA practice
- Publication number “CN112…” usually corresponds to publication around the late 2020–2021 period for applications filed in 2019–2020.
- Grant status is determined by whether it advanced through substantive examination and allowance.
Landscape relevance
- For competitors, the key question is whether CN112654356 is granted (enforceable) or only published (not directly enforceable, but used in freedom-to-operate assessments and invalidity challenges).
- For investors/licensors, the presence of granted claims (and their breadth) drives valuation more than the existence of the publication itself.
How does CN112654356 interact with China generics, reforms, and patent linkage?
China’s patent landscape for drugs is shaped by:
- Patent linkage for NMPA/MAH approvals in the “listed patents” framework (where applicable to the product and claim type).
- Invalidity and infringement proceedings in parallel to generic application review.
Landscape mechanisms that matter for CN112654356
- If CN112654356 is (or becomes) part of listed patents for the reference medicine, it can delay generic approval tied to the same dosage form and claim scope.
- Even if not listed, it can still function as an infringement threat and force design-around development.
Design-around levers competitors commonly use in China
- Changing excipient system while keeping the drug.
- Moving to alternative dosage forms.
- Adjusting concentrations so the formulation no longer meets claimed numeric ranges.
- Changing manufacturing process so process-dependent claims do not read on the product.
Who are the likely competitive pressure points (generic and formulation developers)?
Given CN drug filings generally protect either the drug formulation, manufacturing route, or an improvement variant, the pressure points are typically:
- Generic API suppliers seeking to market a same-IU (ingredient-unit) drug in the same dosage form.
- Formulation-only specialists developing alternate dosage forms or improved release profiles.
- IM/MAH incumbents defending their lifecycle through incremental formulation patents.
Where CN112654356 matters most
- If it claims a specific dosage form (for example, controlled-release tablets or a specific lyophilized injection structure), competitors must align their product with the claim boundary to avoid both infringement and listing delays.
- If it claims process-defined nanoparticles/solid dispersions, competitors may use different particle engineering to exit the claim.
What is the likely validity risk (obviousness, support, enablement) in China?
Validity challenges in CNPI practice for formulation/device-adjacent pharmaceutical claims often hinge on:
- Novelty: whether identical formulation appears in earlier publications or patents.
- Inventive step: whether the claimed formulation is an obvious optimization of known compositions.
- Sufficiency of disclosure: whether the specification enables the full claimed scope.
- Clarity: whether metrics and ranges are measurable and clearly defined.
How claim language affects risk
- Broad “selected from” excipient recitations and wide quantitative ranges increase the chance that prior art renders the claim obvious.
- Tight ranges plus linked performance metrics usually reduce obviousness risk but raise enablement and reproducibility questions.
How should you benchmark CN112654356 against neighboring China filings (landscape mapping)?
A proper landscape map for CN112654356 should cluster:
- Same active ingredient formulation patents in China (same dosage forms and excipient systems).
- Same performance target patents (dissolution, bioavailability improvement, stability).
- Same process patents (granulation method, milling/particle size, sterilization/lyophilization protocols).
- Same molecule polymorph/hydrate forms if included in the claims.
What to look for in each cluster
- Filing dates and priority.
- Claim breadth and whether independent claims are composition-only or also process/performance.
- Whether later patents cite or distinguish CN112654356.
Key takeaways
- CN112654356’s enforceable scope is determined by how the independent claims define the active ingredient/formulation components, quantitative ranges, dosage form, and any method or performance metrics.
- The main infringement risk for competitors is when their product is within the claimed composition boundaries (and, if applicable, manufacturing conditions or performance-defined metrics).
- The China landscape impact depends on whether CN112654356 is granted and whether its claims align with listed patent mechanisms for the corresponding reference product and dosage form.
- For R&D/design-around, the highest-value strategy is to test whether alternative excipient systems, dosage forms, or process controls can move outside the claim-relevant ranges and definitions.
FAQs
1) What determines whether an accused generic infringes CN112654356?
Whether the accused product falls within the claimed composition/formulation elements and numeric ranges, and, where present, any process steps/conditions and performance metrics recited in the claims.
2) Does CN112654356 typically protect only a composition or also a method?
Most CN drug formulation filings protect either (a) composition/dosage form and dependent formulation variants, (b) a preparation method, or (c) both. The legal boundary depends on whether independent and dependent claims include method steps or only product composition.
3) How does claim dependency affect freedom-to-operate analysis?
Dependent claims narrow the scope. FTO teams must test literal coverage against the independent claim first, then map whether the accused product matches any dependent claim constraints that could independently support infringement.
4) What is the fastest way to design around a formulation patent in China?
Change at least one claim-critical element: drug concentration range, required excipients/ratios, dosage form definition, particle size/polymorph attributes, or process parameters if method claims exist.
5) How do validity challenges in China usually attack formulation patents like CN112654356?
They target novelty, inventive step (obviousness), sufficiency/enablement, and claim clarity, especially when the claimed ranges or performance metrics are broad or insufficiently supported.
References (APA)
[1] CNIPA. CN112654356 (publication record and bibliographic details).
